白宫近日确认，特朗普将在三月底开启他的访华行程，整个访问周期将仅持续数日。美方提前一个多月高调宣布这一消息，显然意在展示自己手中握有重要 筹码，准备与中方展开深入对话。外界本来普遍预期，特朗普会把全球对等关税作为自己最强的底牌，通过单边施压的方式，争取经贸和外交层面的突破。 然而，这一期待还未落地，美国最高法院的一纸裁决就彻底打破了白宫的预设。 2月20日，当地时间，最高法院以六票对三票的结果作出最终裁决，认定特 朗普依赖《国际紧急经济权力法》推行的大规模全球关税措施属于越权行为，违反宪法，必须立刻废止。这一重磅判决的时间点颇为微妙，距离特朗普的访 华行程公布仅剩不到一天，总统专机尚未起飞，华盛顿内部已经先一步爆发了不小的风波。 首席大法官罗伯茨在判决书中明确指出，1977年出台的《紧急 经济权力法》最初的目的，是为了赋予总统在战争或国家安全紧急情况下处理事务的必要手段，绝不是为总统制定一个全球性关税体系提供依据。白宫将这 部法律解读成总统可以单方面、无限制地征收关税的法律依据，显然已经越过了国会赋予的权限边界。这份判决的影响不仅仅是打掉了几项政策条文，更重 的是摧毁了特朗普执政期间最为依赖的对外威慑工具。在 ...

Core Viewpoint - The U.S. Supreme Court has delayed a decision on the global reciprocal tariffs imposed by the Trump administration under the International Emergency Economic Powers Act (IEEPA), leading to uncertainty in the market regarding future trade policies and their economic implications [1][2]. Group 1: Market Reactions and Expectations - The market anticipates that if the IEEPA tariffs are overturned, bond yields may rise due to concerns over fiscal deficits, while stock markets could benefit from eased profit pressures on retailers and a more relaxed fiscal stance [1][10]. - Conversely, if the tariffs are upheld, both bond yields and stock markets are expected to decline, with the market currently leaning towards the expectation of an overturn, which could lead to significant price impacts [10] Group 2: Revenue and Economic Impact - Current tariff revenues are estimated at approximately $30 billion per month, accounting for about 1.2% of GDP, with 55% to 65% of this revenue attributed to IEEPA-related tariffs [7]. - If the IEEPA tariffs are overturned, the government may resort to alternative legal provisions to recover some revenue, potentially leading to a net loss in overall tariff income of about 0.3% of GDP, equating to approximately $90 billion annually [8]. Group 3: Implications for Growth and Inflation - Regardless of the Supreme Court's ruling, trade policies are expected to support economic growth this year, with potential government actions aimed at reducing trade uncertainties and promoting more market-friendly outcomes [11]. - The short-term inflation impact may lean slightly downward, as retailers who have passed on tariff costs may hold prices steady or even reduce them, providing some room for the Federal Reserve to consider further rate cuts [11]. Group 4: Tariff Collection Discrepancies - The effective tariff rate has been lower than expected, currently at 11.2%, significantly below the theoretical rate of 14.5%, due to importers shifting towards lower-tariff products and exemptions [12]. - This discrepancy indicates that the Supreme Court's decision may have a muted impact on the market and macroeconomic conditions, as the actual revenue collected is less than anticipated [12].

Group 1 - The article highlights the increasing pain felt by various industries due to China's rare earth export control measures, prompting foreign manufacturers to accelerate the establishment of their own rare earth supply chains [1][3] - U.S. rare earth manufacturers express confidence in their ability to make significant progress within a year, indicating a strong demand for rare earth resources that have traditionally been supplied by China [1][3] - China controls approximately 70% of global rare earth mining, 85% of refining capacity, and about 90% of rare earth metal alloys and magnet production, showcasing its monopolistic position in the global rare earth processing sector [3] Group 2 - From 2020 to 2023, 70% of U.S. rare earth compounds and metals were imported from China, highlighting the U.S. reliance on Chinese supplies and the determination to reduce this dependency [3] - Some U.S. scholars and media express skepticism about the future of the U.S. rare earth industry, suggesting that the era of U.S. dominance may be coming to an end [3][5] - The U.S. pharmaceutical industry is heavily reliant on China, with over 60% of daily medications and raw materials sourced from China, indicating a significant vulnerability in the U.S. healthcare supply chain [5][7] Group 3 - The article suggests that if the U.S. continues its policies of manufacturing repatriation and tariff threats, it may lead to a situation where American pharmaceutical companies could abandon the U.S. market, resulting in a potential shortage of medications [7] - The actions taken by the U.S. under the Trump administration are portrayed as exposing weaknesses in American hegemony, while China is advised to focus on its own development and respond appropriately to U.S. actions [7]

Core Viewpoint - A group of small businesses is urging the U.S. trade court to block the global reciprocal tariffs initiated by President Trump on April 2, which could significantly impact the Republican economic agenda [1] Group 1: Court Proceedings - The businesses and Trump's government lawyers presented arguments at the U.S. International Trade Court in Manhattan on May 13 [1] - The court, consisting of a three-judge panel, is deliberating whether to issue a nationwide injunction against these tariffs and the duration of such an injunction if granted [1] Group 2: Legal Arguments - The businesses argue that Trump invoked a false national emergency to justify the tariffs, while the Justice Department contends that the President's decision should not be subject to judicial review [1] - The panel has not yet issued a ruling, which will be announced later [1]